CrossAssetDataThe Company File
···
ZLAB

Zai Lab Limited

Zai Lab Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Shanghai. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $457 million and a loss of $176 million (its filed statements).

Product business Pharmaceutical Preparations Shanghai filings since 2017 8 of 9 filed, 1 estimated
Ask the desk about ZLAB → Compare ZLAB with TLX → Price chart on TradingView ↗ Full EDGAR file ↗ Watch ZLAB →

Sector peers: TLXINDVRCUSIDYA

5.9/10headline grade
vs its business-model standard
6.9/10past 6.2/10present 4.6/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.9 out of ten, 8 of 9 metrics filed and 1 estimated: past 6.9 out of ten, present 6.2 out of ten, future 4.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 6.2 out of ten. 3 warning events since 2017; the latest 2022-06-01. 61st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 7.7 out of ten. +221.4% a year over 8 filed years; profitable in 0 of 8. 77th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 6.2 out of ten. CrossAssetData estimate 6.2/10, confidence 35 of 100 (one part). 62nd percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 5.6 out of ten. ROE -25%: lost 25¢ per shareholder dollar. Leverage 39%: owes 39¢ per asset dollar. 56th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.0 out of ten. top 30% of 314 in its family; net margin -38.4%. 70th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 6.1 out of ten. top 39% of 315 in its family for leadership; chief executive since 2021. 61st percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.1 out of ten. top 49% of 272 in its family for room to expand. 51st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 3.2 out of ten. bottom 32% of 307 in its family for growth drivers. 32nd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.6 out of ten. top 44% of 234 in its family for expectations against reality. 56th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 2017. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Zejula 41%, Vyvgart Vyvgart Hytrulo 21%, Nuzyra 13%, Optune 11%, Qinlock 8%, XACDURO 5%. As tagged in its annual report (Form 10-K, filed 2026-02-26).

Who runs it

Du, Ying (Chairperson & CEO); Amado, Rafael (President, Head of Global Oncology Research and Development); Smiley, Joshua L (President and Chief Operating Officer); Chen, Yajing (Chief Financial Officer); Edmondson, Frazor Titus III (Chief Legal Officer); Wang, Yizhe (Operating Partner); Lis, William (director); Gaynor, Richard (director); Diekman, John D (director); Leung, Nisa (director); and 4 more. 14 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.